Reata Pharmaceuticals - RETA Stock Forecast, Price & News

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Reata Pharmaceuticals Stock Down 4.7 %

Shares of RETA Stock traded down $0.93 on Wednesday, hitting $18.80. 12,962 shares of the stock traded hands, compared to its average volume of 674,092. Reata Pharmaceuticals has a 52 week low of $19.68 and a 52 week high of $116.04. The firm has a 50 day simple moving average of $31.12 and a two-hundred day simple moving average of $30.34.

Reata Pharmaceuticals (NASDAQ:RETA - Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($2.02) earnings per share for the quarter, missing the consensus estimate of ($1.90) by ($0.12). The company had revenue of $0.76 million for the quarter, compared to analysts' expectations of $1.46 million. Reata Pharmaceuticals had a negative net margin of 3,045.98% and a negative return on equity of 190.87%. The business's revenue was down 65.7% on a year-over-year basis. During the same period in the previous year, the business posted ($2.00) earnings per share. Sell-side analysts expect that Reata Pharmaceuticals will post -8.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Citigroup upped their price objective on shares of Reata Pharmaceuticals from $43.00 to $46.00 and gave the stock a "buy" rating in a report on Friday, May 27th. LADENBURG THALM/SH SH decreased their price target on shares of Reata Pharmaceuticals from $75.00 to $67.00 in a research report on Wednesday, May 11th. The Goldman Sachs Group decreased their price target on shares of Reata Pharmaceuticals from $93.00 to $73.00 and set a "buy" rating on the stock in a research report on Tuesday, May 24th. Finally, Robert W. Baird decreased their price target on shares of Reata Pharmaceuticals from $37.00 to $27.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Reata Pharmaceuticals presently has an average rating of "Hold" and an average target price of $57.57.